Memory improvement in early Alzheimer’s disease
Souvenaid efficacy was established in the Souvenir I and Souvenir II trials which demonstrated memory improvement in patients with mild AD, taking Souvenaid once-daily over 12 and 24 weeks, respectively [1,2].
Souvenir I demonstrated that Souvenaid significantly improved memory performance (assessed by Wechsler Memory Scale-revised) and was well tolerated over a 12 week period in drug-naïve patients with mild Alzheimer’s disease.
Souvenir II demonstrated that, over a 24-week period, Souvenaid provided significant improvements in memory performance (assessed by a Neuropsychological Test Battery) and was associated with a tolerability profile similar to controls in drug-free patients with mild Alzheimer’s disease.
Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial 
An improvement in memory function has been assessed by the WMS-r test after 12 weeks of consumption of Souvenaid (green) compared to a control drink (grey) .
Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial 
This graph shows the difference in trajectories over time between Souvenaid and control groups during the 24-week intervention period. There was a significant improvement in the memory domain of the NTB over 24 weeks of treatment with Souvenaid . The OLE study indicated that the memory performance significantly increased from week 24 to week 48 in both active-active and control-active groups .
- Scheltens P, et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement. 2010;6:1-10.e1.
- Scheltens P, et al.Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimer’s Dis. 2012;31:225–236.